Healthcare firm Azenta beats Q4 revenue, profit estimates

Azenta

21/11/2025 11:40

Overview

Azenta fiscal Q4 revenue grows 6% yr/yr, beating analyst expectations

Adjusted EPS for fiscal Q4 beats consensus, indicating improved operational performance

Company achieves significant adjusted EBITDA margin expansion, reflecting effective cost management

Outlook

Azenta expects FY26 organic revenue growth of 3% to 5%

Company anticipates FY26 adjusted EBITDA margin to expand by 300 basis points

Result Drivers

MULTIOMICS GROWTH - Revenue in Multiomics increased 11% yr/yr, driven by Next Generation Sequencing and Gene Synthesis

SAMPLE MANAGEMENT - Sample Management Solutions revenue grew 2% yr/yr, driven by Clinical Biostores and Automated Stores

OPERATIONAL EFFICIENCY - Margin expansion attributed to operational improvements and cost discipline

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$159.19 mln
$156.15 mln (8 Analysts)
Q4 Adjusted EPS
Beat
$0.21
$0.19 (8 Analysts)
Q4 Adjusted EBITDA
$21 mln
Q4 Gross Margin
45.40%
Q4 Adjusted EBITDA Margin
13.00%
Q4 EPS from Cont Ops
$1.11
Q4 Operating Income
$1.90 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Azenta Inc is $35.00, about 14.3% above its November 20 closing price of $30.00

The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 45 three months ago

Press Release: ID:nPn152Dr1a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)